LABP News and Press, Landos Biopharma Inc. From 04/29/21

Landos’ second first-in-class product candidate designed to provide a safer and more convenient treatment for ulcerative colitis patients Topline results are expected in the first quarter of 2022 BLACKSBURG, Va., April 29, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (...

Robust preclinical data supports breadth and growth of Landos’ autoimmune-focused pipeline Company expects to submit an IND for omilancor as a topical treatment for psoriasis in 2H 2021 Company expects to submit an IND for PX-69 as an oral treatment for rheumato...

BLACKSBURG, Va., April 13, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the appointment of Tiago Girão to its Board of...

BLACKSBURG, Va., April 06, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) ha...

Landos Biopharma ([[LABP]] -1.1%) has announced that its experimental oral therapy NX-13 met all primary and secondary endpoints in a Phase 1 trial for the treatment of inflammatory bowel disease ("IBD").The randomized, double-blind, placebo-controlled study with single and multiple asce...

NX-13 was well tolerated with no reported serious adverse events All primary and secondary endpoints in the Phase 1 study of NX-13 were met Landos expects to initiate a Phase 1b trial of NX-13 in patients with ulcerative colitis (UC) later this year BLACKSBURG, Va....

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Investors have a variety of events and developments to focus on next week. The impact of the pending FDA approval on Joh...

Two IPOs are scheduled to raise $1.3 billion in the week ahead. Street research is expected for 14 companies. Lock-up periods will be expiring for six companies. For further details see: U.S. IPO Week Ahead: Health Insurer Oscar Health Leads A 2 IPO Week

BLACKSBURG, Va., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (Nasdaq: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced that Dr. Josep Bassaganya-Riera, Chairman, President...